Literature DB >> 3044672

Dialysis-related beta 2 microglobulin-amyloid arthropathy. Improvement of clinical symptoms after a switch of dialysis membranes.

P Hardouin1, R M Flipo, P Foissac-Gegoux, A Dumont, B Duquesnoy, B Delcambre.   

Abstract

Amyloidosis containing beta 2 microglobulin (beta 2m) and joint pains are frequent complications of long-term hemodialysis. In a prospective study the authors planned to act on dialysis arthropathies (DA) by improving beta 2m depuration: for 8 patients suffering from DA we replaced usual cuprophane membranes (CU) by high permeability polyacrylonitrile membranes (PAN). DA was diagnosed on the presence of severe disabling arthralgias in the absence of any other obvious etiology, and on the presence of at least 3 among 6 criteria. The efficacy of the switch of DM was assessed on 6 criteria including the patient's own evaluation at the end of the study and a joint pain severity index. Clinical evaluation and beta 2m measurement were carried out at the start of the trial and after a mean duration of dialysis on PAN of 6 months. An improvement in joint symptomatology and a decrease of joint severity index were noted in the 8 cases. Our results suggest that the change of DM has a favorable influence on DA. This improvement could result either from a better beta 2m depuration or from a better biocompatibility of PAN than the CU previously used.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044672     DOI: 10.1007/BF02284055

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  Dialysis arthropathy: complication of long term treatment with haemodialysis.

Authors:  J M Vandenbroucke; J P Huaux; C Nagant de Deuxchaisnes; C van Ypersele de Strihou
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

2.  [Continuous ambulatory peritoneal dialysis amelioration of abarticular pain associated with carpal tunnel syndrome in hemodialysis patients].

Authors:  G Laurent; B Charra; E Calemard; M Uzan; T Vanel; J C Terrat
Journal:  Presse Med       Date:  1985-11-30       Impact factor: 1.228

3.  [Toward amyloidosis prevention in hemodialyzed patients. Study of capacity for filtering beta-2-microglobulin by different membranes].

Authors:  P Foissac-Gegoux; P Hardouin; R M Flipo; A Dumont; B Delcambre
Journal:  Presse Med       Date:  1987-03-21       Impact factor: 1.228

4.  Destructive spondylarthropathy in hemodialyzed patients: possible role of amyloidosis.

Authors:  J L Sebert; P Fardellone; A Marie; H Deramond; G Lambrey; D Legars; P Galibert; A Smajda; A Fournier
Journal:  Arthritis Rheum       Date:  1986-02

5.  Haemodialysis membranes, serum beta 2-microglobulin, and dialysis amyloidosis.

Authors:  D Hauglustaine; M Waer; P Michielsen; J Goebels; M Vandeputte
Journal:  Lancet       Date:  1986-05-24       Impact factor: 79.321

6.  [Articular amyloidosis, femoral neck fracture and chronic periodic hemodialysis].

Authors:  J P Huaux; H Noël; P Bastien; J Malghem; B Maldague; J P Devogelaer; C Nagant de Deuxchaisnes
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-03

7.  Side effects of hemodialysis.

Authors:  G Eknoyan
Journal:  N Engl J Med       Date:  1984-10-04       Impact factor: 91.245

8.  Beta-2 microglobulin is an amyloidogenic protein in man.

Authors:  P D Gorevic; T T Casey; W J Stone; C R DiRaimondo; F C Prelli; B Frangione
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  Hemodialysis leukopenia and complement function with different dialyzers.

Authors:  A Amadori; P Candi; M Sasdelli; G Massai; S Favilla; A Passaleva; M Ricci
Journal:  Kidney Int       Date:  1983-12       Impact factor: 10.612

10.  Complement activation and hypersensitivity reactions to dialysis membranes.

Authors:  R M Hakim; J Breillatt; J M Lazarus; F K Port
Journal:  N Engl J Med       Date:  1984-10-04       Impact factor: 91.245

View more
  1 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.